Mingzhen Yang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Mingzhen Yang has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Jiqin Lian
Department of Clinical Biochemistry, Army Medical University (Third Military Medical University), Chongqing, China
8 shared publications - Dun Niu
Department of Clinical Biochemistry, Faculty of Pharmacy and Laboratory Medicine, Army Medical University, Chongqing, China
7 shared publications - Jianglang Ran
Department of Clinical Biochemistry, Faculty of Pharmacy and Laboratory Medicine, Army Medical University, Chongqing, China
7 shared publications - Junshi Zhu
Department of Clinical Biochemistry, Faculty of Pharmacy and Laboratory Medicine, Army Medical University, Chongqing, China
7 shared publications - Lu Lu
Department of Clinical Biochemistry, Faculty of Pharmacy and Laboratory Medicine, Army Medical University, Chongqing, China
7 shared publications - Meihua Shan
Department of Clinical Biochemistry, Faculty of Pharmacy and Laboratory Medicine, Army Medical University, Chongqing, China
7 shared publications
Latest Publications
- Open Access
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from Intratumoral Administration of Engineered circRNAs Encoding Cytosine Deaminase–Uracil Phosphoribosyltransferase and IL-15 Elicits Superior Antitumor Efficacy
Comparison of the CDUPRT distribution, anti-tumor capacity and toxicity of mCDUPRT versus circCDUPRT after intravenous or intratumoral administration.
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from Intratumoral Administration of Engineered circRNAs Encoding Cytosine Deaminase–Uracil Phosphoribosyltransferase and IL-15 Elicits Superior Antitumor Efficacy
Comparison of the CDUPRT distribution, anti-tumor capacity and toxicity of mCDUPRT versus circCDUPRT after intravenous or intratumoral administration.
- Open Access
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Intratumoral Administration of Engineered circRNAs Encoding Cytosine Deaminase–Uracil Phosphoribosyltransferase and IL-15 Elicits Superior Antitumor Efficacy
The chemical structure of the 5-Flucytosine (5-FC), 5-Fluorouraci (5-FU) and 5-Fluoro-deoxyuridine monophosphate (5-FUMP).
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Intratumoral Administration of Engineered circRNAs Encoding Cytosine Deaminase–Uracil Phosphoribosyltransferase and IL-15 Elicits Superior Antitumor Efficacy
The chemical structure of the 5-Flucytosine (5-FC), 5-Fluorouraci (5-FU) and 5-Fluoro-deoxyuridine monophosphate (5-FUMP).
- Open Access
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Intratumoral Administration of Engineered circRNAs Encoding Cytosine Deaminase–Uracil Phosphoribosyltransferase and IL-15 Elicits Superior Antitumor Efficacy
The sequences of circGFP, circCDUPRT, circIL, and circScram
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Intratumoral Administration of Engineered circRNAs Encoding Cytosine Deaminase–Uracil Phosphoribosyltransferase and IL-15 Elicits Superior Antitumor Efficacy
The sequences of circGFP, circCDUPRT, circIL, and circScram
- Open Access
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Intratumoral Administration of Engineered circRNAs Encoding Cytosine Deaminase–Uracil Phosphoribosyltransferase and IL-15 Elicits Superior Antitumor Efficacy
Comparison of mCDUPRT and circCDUPRT in vitro anti-tumor ability, protein translation ability and prodrug transformation ability under different concentrations and times.
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Intratumoral Administration of Engineered circRNAs Encoding Cytosine Deaminase–Uracil Phosphoribosyltransferase and IL-15 Elicits Superior Antitumor Efficacy
Comparison of mCDUPRT and circCDUPRT in vitro anti-tumor ability, protein translation ability and prodrug transformation ability under different concentrations and times.
- Open Access
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Data from Intratumoral Administration of Engineered circRNAs Encoding Cytosine Deaminase–Uracil Phosphoribosyltransferase and IL-15 Elicits Superior Antitumor Efficacy
Gene-directed enzyme prodrug therapy represents a promising antitumor strategy owing to its low systemic toxicity. However, clinical translation has been hindered by challenges in suicide gene delivery. Artificially engineered circular RNA (circRNA) demonstrates exceptional potential for gene delivery when combined with lipid nanoparticle technology, exhibiting high stability, prolonged protein-coding capacity, and cost-effective production. We developed an in vitro synthesized circRNA encoding the cytosine deaminase–uracil phosphoribosyltransferase (circCDUPRT). Upon intratumoral administration, circCDUPRT achieved sustained intratumoral expression with minimal systemic toxicity. The combination of circCDUPRT and prodrug 5-fluorocytosine showed significant antitumor efficacy in both in vitro and in vivo tumor models. In advanced melanoma models, combining circCDUPRT/5-fluorocytosine with IL-15–expressing circRNA potently enhanced the expansion and activation of CD8+ T and NK cells. Collectively, these findings establish the synthetic circRNA platform as a cost-effective, high-efficiency delivery system for gene-directed enzyme prodrug therapy and immunotherapy applications.
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Intratumoral Administration of Engineered circRNAs Encoding Cytosine Deaminase–Uracil Phosphoribosyltransferase and IL-15 Elicits Superior Antitumor Efficacy
Gene-directed enzyme prodrug therapy represents a promising antitumor strategy owing to its low systemic toxicity. However, clinical translation has been hindered by challenges in suicide gene delivery. Artificially engineered circular RNA (circRNA) demonstrates exceptional potential for gene delivery when combined with lipid nanoparticle technology, exhibiting high stability, prolonged protein-coding capacity, and cost-effective production. We developed an in vitro synthesized circRNA encoding the cytosine deaminase–uracil phosphoribosyltransferase (circCDUPRT). Upon intratumoral administration, circCDUPRT achieved sustained intratumoral expression with minimal systemic toxicity. The combination of circCDUPRT and prodrug 5-fluorocytosine showed significant antitumor efficacy in both in vitro and in vivo tumor models. In advanced melanoma models, combining circCDUPRT/5-fluorocytosine with IL-15–expressing circRNA potently enhanced the expansion and activation of CD8+ T and NK cells. Collectively, these findings establish the synthetic circRNA platform as a cost-effective, high-efficiency delivery system for gene-directed enzyme prodrug therapy and immunotherapy applications.
- Open Access
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from Intratumoral Administration of Engineered circRNAs Encoding Cytosine Deaminase–Uracil Phosphoribosyltransferase and IL-15 Elicits Superior Antitumor Efficacy
Validation of the tumor-targeting capacity and low toxicity of circCDUPRT on a 4T1 tumor-bearing mouse model.
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from Intratumoral Administration of Engineered circRNAs Encoding Cytosine Deaminase–Uracil Phosphoribosyltransferase and IL-15 Elicits Superior Antitumor Efficacy
Validation of the tumor-targeting capacity and low toxicity of circCDUPRT on a 4T1 tumor-bearing mouse model.
- 30 September 2025
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 25 (2) , 272-282
Intratumoral Administration of Engineered circRNAs Encoding Cytosine Deaminase–Uracil Phosphoribosyltransferase and IL-15 Elicits Superior Antitumor Efficacy
Gene-directed enzyme prodrug therapy represents a promising antitumor strategy owing to its low systemic toxicity. However, clinical translation has been hindered by challenges in suicide gene delivery. Artificially engineered circular RNA (circRNA) demonstrates exceptional potential for gene delivery when combined with lipid nanoparticle technology, exhibiting high stability, prolonged protein-coding capacity, and cost-effective production. We developed an in vitro synthesized circRNA encoding the cytosine deaminase–uracil phosphoribosyltransferase (circCDUPRT). Upon intratumoral administration, circCDUPRT achieved sustained intratumoral expression with minimal systemic toxicity. The combination of circCDUPRT and prodrug 5-fluorocytosine showed significant antitumor efficacy in both in vitro and in vivo tumor models. In advanced melanoma models, combining circCDUPRT/5-fluorocytosine with IL-15–expressing circRNA potently enhanced the expansion and activation of CD8+ T and NK cells. Collectively, these findings establish the synthetic circRNA platform as a cost-effective, high-efficiency delivery system for gene-directed enzyme prodrug therapy and immunotherapy applications.
- 30 September 2025
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 25 (2) , 272-282
Intratumoral Administration of Engineered circRNAs Encoding Cytosine Deaminase–Uracil Phosphoribosyltransferase and IL-15 Elicits Superior Antitumor Efficacy
Gene-directed enzyme prodrug therapy represents a promising antitumor strategy owing to its low systemic toxicity. However, clinical translation has been hindered by challenges in suicide gene delivery. Artificially engineered circular RNA (circRNA) demonstrates exceptional potential for gene delivery when combined with lipid nanoparticle technology, exhibiting high stability, prolonged protein-coding capacity, and cost-effective production. We developed an in vitro synthesized circRNA encoding the cytosine deaminase–uracil phosphoribosyltransferase (circCDUPRT). Upon intratumoral administration, circCDUPRT achieved sustained intratumoral expression with minimal systemic toxicity. The combination of circCDUPRT and prodrug 5-fluorocytosine showed significant antitumor efficacy in both in vitro and in vivo tumor models. In advanced melanoma models, combining circCDUPRT/5-fluorocytosine with IL-15–expressing circRNA potently enhanced the expansion and activation of CD8+ T and NK cells. Collectively, these findings establish the synthetic circRNA platform as a cost-effective, high-efficiency delivery system for gene-directed enzyme prodrug therapy and immunotherapy applications.
- 1 September 2021
- Published by Elsevier in Experimental Cell Research
- Vol. 406 (1) , 112755
Dichloroacetate enhances the anti-tumor effect of sorafenib via modulating the ROS-JNK-Mcl-1 pathway in liver cancer cells
- 1 September 2021
- Published by Elsevier in Experimental Cell Research
- Vol. 406 (1) , 112755
Dichloroacetate enhances the anti-tumor effect of sorafenib via modulating the ROS-JNK-Mcl-1 pathway in liver cancer cells
- Open Access
- 4 August 2016
- Published by Royal Society of Chemistry (RSC) in Chemical Science
- Vol. 7 (12) , 7094-7100
Competitive method-based electrochemiluminescent assay with protein–nucleotide conversion for ratio detection to efficiently monitor the drug resistance of cancer cells
A simple and highly-efficient approach to monitor the expression of P-glycoprotein (P-gp) in cells was urgently needed to demonstrate the drug resistance of cancer cells. Herein, a competitive method-based electrochemiluminescent (ECL) assay with a single ECL indicator was proposed for the first time to efficiently estimate the concentration ratio of two proteins. By converting the different proteins to partially coincident nucleotide sequences via a sandwich type immunoassay on magnetic beads, the concentration ratio related ECL signals could be obtained via competitive nucleotide hybridization on an electrode surface. This method could thoroughly overcome the limitations of simultaneous ECL assays via multiple ECL indicators with inevitable cross reactions. At the same time, rolling circle amplification was employed to improve the detection performances, especially the detection limit and sensitivity. With P-gp and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as a model, the proposed ECL assay was successfully employed to monitor the drug resistance of cancer cells. Compared with conventional technologies, improved sensitivity and accuracy were achieved with a correlation coefficient of 0.9928 and a detection limit of 0.52%. Success in the establishment of the competitive method-based ECL assay offered an efficient strategy to demonstrate the concentration ratio of two proteins and a potential approach for detecting other proteins and nucleotide sequences, revealing a new avenue for ultrasensitive biomolecule diagnostics, especially in cell function research.
- 4 August 2016
- Published by Royal Society of Chemistry (RSC) in Chemical Science
- Vol. 7 (12) , 7094-7100
Open AccessCompetitive method-based electrochemiluminescent assay with protein–nucleotide conversion for ratio detection to efficiently monitor the drug resistance of cancer cells
A simple and highly-efficient approach to monitor the expression of P-glycoprotein (P-gp) in cells was urgently needed to demonstrate the drug resistance of cancer cells. Herein, a competitive method-based electrochemiluminescent (ECL) assay with a single ECL indicator was proposed for the first time to efficiently estimate the concentration ratio of two proteins. By converting the different proteins to partially coincident nucleotide sequences via a sandwich type immunoassay on magnetic beads, the concentration ratio related ECL signals could be obtained via competitive nucleotide hybridization on an electrode surface. This method could thoroughly overcome the limitations of simultaneous ECL assays via multiple ECL indicators with inevitable cross reactions. At the same time, rolling circle amplification was employed to improve the detection performances, especially the detection limit and sensitivity. With P-gp and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as a model, the proposed ECL assay was successfully employed to monitor the drug resistance of cancer cells. Compared with conventional technologies, improved sensitivity and accuracy were achieved with a correlation coefficient of 0.9928 and a detection limit of 0.52%. Success in the establishment of the competitive method-based ECL assay offered an efficient strategy to demonstrate the concentration ratio of two proteins and a potential approach for detecting other proteins and nucleotide sequences, revealing a new avenue for ultrasensitive biomolecule diagnostics, especially in cell function research.